BioSpace News Archive

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the closing of its previously announced exclusive license agreement with GSK plc (LSE/NYSE: GSK) to commercialize the novel antifungal BREXAFEMME® (ibrexafungerp tablets) as a treatment for vulvovaginal candidiasis (VVC) and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the first quarter 2023 and provided a corporate update.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the first quarter ended March 31, 2023.

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced an upcoming poster presentation featuring new clinical data from its Phase 1 clinical study of UPB-101 at the American Thoracic Society (ATS) International Conference, happening May 19-24 in Washington, DC.

SAB Biotherapeutics (Nasdaq: SABS), (SAB) today announced the publication of nonclinical data in the medical journal Antibodies.

Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.

Hoth Therapeutics, Inc., a patient focused biopharmaceutical company, announced that they have entered into a mutual agreement with Algorithm Sciences, Inc. to terminate their previously announced decision to merge, originally announced on April 26, 2023.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announced that it will host its Fiscal Year 2022 Financial Results and Business Update Call on Tuesday, May 16, 2023.